CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 651 - 660 of 730
Study Number Lead Group Study Title CIRB Study Status
S0337 SWOG A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Adult CIRB - Late Phase Emphasis Completed
S0347 SWOG A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III Adult CIRB - Late Phase Emphasis Completed
S0421 SWOG Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer Adult CIRB - Late Phase Emphasis Completed
S0427 SWOG A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin; with and without Docetaxel; Cisplatin; and 5-FluorouracilInduction Chemotherapy; in Patients with Advanced Oropharyngeal Squamous Cell Cancer Adult CIRB - Late Phase Emphasis Completed
S0500 SWOG A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment Adult CIRB - Late Phase Emphasis Completed
S0502 SWOG A Phase III Randomized Study of Imatinib; with or without Bevacizumab (NSC-704865); in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT #00324987 Adult CIRB - Late Phase Emphasis Completed
S0518 SWOG Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced; Poor Prognosis Carcinoid Patients Adult CIRB - Late Phase Emphasis Available to Open
S0521 SWOG A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL); Phase III Adult CIRB - Late Phase Emphasis Completed
S0600 SWOG Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX Adult CIRB - Late Phase Emphasis Completed
S0777 SWOG A Randomized Phase III Trial of CC-5013 (Lenalidomide; NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341; NSC-681239); Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction; in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant Adult CIRB - Late Phase Emphasis Available to Open
Displaying 651 - 660 of 730